Welcome to our dedicated page for Vanda Pharmaceuticals news (Ticker: VNDA), a resource for investors and traders seeking the latest updates and insights on Vanda Pharmaceuticals stock.
Vanda Pharmaceuticals Inc., traded under the symbol VNDA on Nasdaq, is a specialty biopharmaceutical company dedicated to the development and commercialization of innovative therapies. Vanda's primary focus is on addressing high unmet medical needs to improve the lives of patients. The company's commercial portfolio includes HETLIOZ for Non-24-Hour Sleep-Wake Disorder and nighttime sleep disturbances in Smith-Magenis Syndrome, and Fanapt for schizophrenia. Recently added to its portfolio is PONVORY, a treatment for multiple sclerosis.
Other promising products in Vanda's pipeline include VHX-896, ASO Molecules, VQW-765, Tradipitant (in clinical studies for gastroparesis and motion sickness), and VTR-297. Vanda's robust R&D efforts are highlighted by substantial advancements, such as the initiation of clinical programs in conditions like depression, psoriasis, ulcerative colitis, and pediatric insomnia.
In recent financial news, Vanda reported a net loss of $4.1 million for Q1 2024, a shift from a net income of $3.3 million in Q1 2023. Despite this, the company maintains a strong cash position and expects significant growth from upcoming milestones, including the launch of Fanapt in acute bipolar I disorder and PONVORY in multiple sclerosis.
Recently, Vanda made headlines with the FDA approval of tradipitant for preventing vomiting induced by motion sickness, and the commencement of a comprehensive marketing program for PONVORY following its acquisition from a Johnson & Johnson company. Additional corporate activities involve evaluating unsolicited acquisition proposals, indicating a strategic interest in Vanda’s innovative portfolio.
For more detailed information, investors can visit www.vandapharma.com and follow Vanda on social media platforms.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced disappointing results from the Phase III study of tradipitant for treating gastroparesis, as it failed to meet its primary endpoint on nausea reduction. However, exploratory analyses suggest that the drug may have significant benefits when accounting for certain patient factors. Tradipitant demonstrated a similar safety profile to placebo, with diarrhea as the most common side effect. Vanda plans further data analysis and intends to pursue regulatory submissions, emphasizing their commitment to addressing unmet medical needs in gastroparesis.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced a License Agreement with MSN Pharmaceuticals and Impax Laboratories to resolve patent litigation over the generic version of its drug HETLIOZ (tasimelteon). The agreement allows MSN and Impax to market their version of HETLIOZ in the U.S. starting March 13, 2035, or July 27, 2035, if Vanda obtains pediatric exclusivity. The settlement includes a release of all claims from the litigation and is pending review by the U.S. Federal Trade Commission and the U.S. Department of Justice.
Vanda Pharmaceuticals (Nasdaq: VNDA) announced its participation in significant investor conferences this November, including the Stifel 2021 Virtual Healthcare Conference on November 15, 2021, and the Jefferies 2021 London Healthcare Conference on November 18-19, 2021. A corporate presentation will be available at the Stifel conference, while an on-demand fireside chat will be accessible for the Jefferies event. Investors can access presentations via Vanda's website, with archived content available for 30 days post-event.
Vanda Pharmaceuticals (VNDA) reported strong financial growth in Q3 2021, with total product sales of $70.1 million, a 16% increase from $60.3 million in Q3 2020. HETLIOZ® sales rose 15% to $45.6 million, while Fanapt® sales climbed 18% to $24.5 million. Net income reached $7.8 million, up from $5.9 million year-over-year. However, Vanda revised its HETLIOZ® sales guidance downward due to escalating reimbursement challenges, now estimating $170 to $190 million for 2021. The company anticipates results from a pivotal Phase III study on tradipitant in gastroparesis by year-end.
Vanda Pharmaceuticals Inc. (Nasdaq: VNDA) will announce its third quarter 2021 financial results on November 3, 2021, after market close. A conference call will follow at 4:30 PM ET, where management will discuss the results and corporate activities. Investors can join the call by dialing 1-866-688-9426 domestically or 1-409-216-0816 internationally, with passcode 5961858. The call will also be accessible via Vanda's website and available for replay starting at 7:30 PM ET on the same day until November 10, 2021.
Vanda Pharmaceuticals (Nasdaq: VNDA) has announced its participation in Evercore ISI's Catalyst Day on October 18, 2021. CEO Mihael H. Polymeropoulos will engage in a virtual fireside chat at 1:30 PM ET. Vanda Pharmaceuticals focuses on developing innovative therapies for unmet medical needs. For further details, visit www.vandapharma.com.
Vanda Pharmaceuticals Inc. (VNDA) announced its participation in the Citi 16th Annual BioPharma Virtual Conference from September 8 to September 10, 2021. The company's management will conduct investor meetings during the event. Vanda has also updated its corporate presentation, available on its website under the Investors tab. Vanda Pharmaceuticals is dedicated to developing innovative therapies to meet significant medical needs.
Vanda Pharmaceuticals (Nasdaq: VNDA) has announced the closure of enrollment in the ODYSSEY study, which aimed to compare tradipitant and placebo in hospitalized COVID-19 pneumonia patients. The study was terminated after meeting pre-defined futility criteria, suggesting it was unlikely to achieve its primary endpoint of treatment efficacy. A total of 153 patients were enrolled against a goal of 324. Despite this, Vanda will proceed with genetic analysis to explore susceptibility factors related to severe pneumonia in COVID-19 patients.
Vanda Pharmaceuticals (Nasdaq: VNDA) reported Q2 2021 financial results with total net product sales reaching $67.9 million, a 9% increase year-over-year. HETLIOZ® sales grew 7% to $44.5 million, while Fanapt® saw a 13% increase to $23.4 million. Net income was $9.7 million, up from $8.7 million in Q2 2020. For the first half of 2021, total sales rose 9% to $130.6 million, and cash reserves were $396.5 million. The Phase III trial of tradipitant for gastroparesis is nearing completion, with results expected by year-end 2021.
Vanda Pharmaceuticals (Nasdaq: VNDA) will release its second quarter 2021 financial results on July 28, 2021, after market close. A conference call is scheduled for 4:30 PM ET the same day to discuss the results and corporate activities. Investors can access the call by dialing 1-866-688-9426 for domestic calls or 1-409-216-0816 internationally. The call will also be available on the company's website, with a replay option from 7:30 PM ET on July 28 until 7:30 PM ET on August 4, 2021.
FAQ
What is the current stock price of Vanda Pharmaceuticals (VNDA)?
What is the market cap of Vanda Pharmaceuticals (VNDA)?
What does Vanda Pharmaceuticals Inc. specialize in?
Which products are currently in Vanda's commercial portfolio?
What is HETLIOZ used for?
What is the latest financial update from Vanda?
What significant milestones does Vanda expect in the near future?
What recent product approval has Vanda received?
What is PONVORY, and what does it treat?
What recent corporate actions has Vanda undertaken?
How can investors access Vanda’s financial results conference call?
Where can I find more information about Vanda Pharmaceuticals?
